Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
Key facts
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 416 people, planned
- Starts
- 1 Apr 2027
- Expected to end
- 31 Dec 2032
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Echinocandins
- Placebo (0.9% Sodium chloride) infusion
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Immunocompromised adults (≥18 years old) in an emergency department or hospital with a proven or probable diagnosis of PCP
- Severe PCP, defined as proven or probable PCP with new or increased PCP-attributable hypoxemic respiratory failure meeting at least one of the following criteria: a requirement for ≥4 L/min supplemental oxygen by nasal cannula to maintain oxygenation >94%; a requirement for FiO₂ ≥0.35 via a controlled oxygen-delivery device; or a requirement for advanced respiratory support, including invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). For patients with chronic baseline oxygen use, the increased support must be attributable to PCP
- Currently receiving, or eligible to receive, systemic anti-PCP therapy for the current episode. Patients receiving empiric PCP treatment may be enrolled before microbiological or pathological results are available if results are expected within 1 week
- No later than 48 hours after screening for inclusion and before more than 3 days of PCP therapy have elapsed
- Provision of informed consent by the participant or substitute decision maker, as locally applicable; Clinical Exclusion Criteria
- More than 3 days of effective anti-PCP therapy before enrolment in ECHINO-PCP
- Another infection or clinical indication that independently requires echinocandin therapy
- Known allergy or hypersensitivity to echinocandins
- Receipt of more than 24 hours of caspofungin, micafungin, or anidulafungin, or receipt of one dose of rezafungin, before enrolment
- PCP is no longer considered the most likely diagnosis at the time of randomization
- PCP therapy has already been escalated or changed for presumed treatment failure before enrolment
- Death is deemed imminent (<48 hours), as determined by the treating team and site investigator
- Treatment with antifungals is inconsistent with the patient's advanced care directives; Administrative Exclusion Criteria
- Inability to obtain informed consent, or refusal to consent by the patient or substitute decision maker
- Treating team declines participation
- Inability to ensure reliable follow-up (e.g., lack of means of communication or patient non-resident of the jurisdiction)
- Prior enrolment in ECHINO-PCP
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Preclinical studies and retrospective clinical data suggest that adjunctive echinocandin therapy may improve outcomes in adults with severe Pneumocystis jirovecii pneumonia (PCP). However, the benefit of adding an echinocandin to standard PCP treatment has not been established in a definitive randomized controlled trial. The aim of this trial is:
Read full original descriptionShow less
1. In adults hospitalized with severe PCP, to determine whether adding an echinocandin to standard anti-PCP therapy improves net clinical outcomes by Day 30 compared with standard anti-PCP therapy plus matching placebo.
The 2 groups in the trial
- EchinocandinTreatment being tested
Echinocandin IV + standard anti-PCP therapy until discharge or 7 days, whichever occurs first.
Treatment: Echinocandins
- PlaceboPlacebo, for comparison
0.9% sodium chloride IV placebo + standard anti-PCP therapy until discharge or 7 days, whichever occurs first.
Treatment: Placebo (0.9% Sodium chloride) infusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunctive Echinocandin for Severe Pneumocystis Jirovecii Pneumonia (ECHINO-PCP)
- Record updated
- 5 November 2026